ClinicalTrials.gg
TerminatedNCT04002622Updated Jan 25, 2021

Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

A Phase 2 interventional study of TQB2450 in Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL), sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 18 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-25.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
The population of target indication is small and screening is difficult.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

02

Conditions studied

  • Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)

Browse trials for

03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. confirmed primary mediastinal large B-cell lymphoma.

      1. 18 and 75 years; (ECOG) performance status score of 0 or 1; > 3 months.
      1. At least one . 4. (LVEF) measured by the cardiac echocardiography ≥ 50%.
      1. Screening laboratory values must meet the following criteria: ≥ 80 g/L; neutrophils ≥ 1.5*10\^9/L; ≥ 100 x 10\^9/ L.
      1. Understood and signed an form.

Exclusion criteria

Exclusion Criteria:

    1. to recombinant humanized monoclonal Abm or its components.

      1. Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody ,or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
      1. Has received chemotherapy, surgery, radiotherapy, the last treatment from the first dose less than 4 weeks, or oral targeted drugs for less than 5 half-lives, or oral fluorouracil pyridine drugs for less than 14 days, mitomycin C and nitrosourea for less than 6 weeks.
      1. Has received emergency cytoreductive surgery to control tumors. 5. Has received hematopoietic stem cell transplantation within the last 5 years.
      1. Has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1.
      1. Has diagnosed and/or treated additional within 5 years prior to randomization. Exceptions include basal cell skin cancer, squamous cell carcinoma of skin, melanoma skin and cancer carcinoma in situ of the cervix.
      1. Has definite central nervous system (CNS) infiltration of lymphoma, including brain parenchyma, meningeal invasion or spinal cord compression.
      1. Has any active disease or a history of autoimmune disease. 10. Has serious or uncontrolled diseases such as history of chronic heart failure.
      1. Has any active autoimmune disease or a history of autoimmune disease. 12. Has received blood transfusion, erythropoietin granulocyte colony stimulating factor(G -CSF),or Granulocyte macrophage colony stimulating factor(GM-CSF) within 4 weeks before the first dose.
      1. Has vaccinated with vaccines or attenuated vaccines within 4 weeks before the first dose.
      1. Has received surgery, or unhealed wounds within 4 weeks before the first dose.
      1. Has Hepatic, renal, blood coagulation dysfunction. 16. Has interstitial lung disease or non-infectious pneumonia and present residual lesions.
      1. Has received systemic treatment for active infection before the first dose.
      1. Has active or latent tuberculosis. 19. virus surface antigen (HBsAg) positive, and hepatitis B virus DNA copy number > .
      1. antibody positive , antibody (HCV-Ab) and hepatitis C virus DNA copy number > upper limit of normal.
      1. Breastfeeding or pregnant women. 22. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    TQB2450

    TQB2450 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.

    Drug: TQB2450

Interventions

  • TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Percentage of subjects achieving complete response (CR) and partial response (PR).

    Time frame: up to 96 weeks

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: up to 96 weeks

  2. Duration of Response (DOR)

    DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.

    Time frame: up to 96 weeks

  3. Disease Control Rate (DCR)

    Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 24 months

  4. Time to Response (TTR)

    TTR defined as time from the first dose to the first assessment of PR or CR.

    Time frame: up to 24 months

  5. Overall Survival (OS)

    OS defined as the time from randomization to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: up to 24 months

07

Study locations

18 sites
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • Fifth Medical Center of the Chinese People's Liberation Army General Hospital
    Beijing, Beijing 100071, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100083, China
  • Peking University Third Hospital
    Beijin, Beijing 100191, China
  • Peking Hospital
    Beijin, Beijing 100730, China
  • Union Medical College Hospital Affiliated to Fujian Medical University
    Fuzhou, Fujian 350000, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Cancer Hospital Affiliated to Harbin Medical University
    Ha'erbin, Heilongjiang 150081, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
  • Henan People's Hospital
    Zhengzhou, Henan 450003, China
  • Hunan Canser Hospital
    Changsha, Hunan 410006, China
  • First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250000, China
  • Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266005, China
  • Shanghai Tongji Hospital
    Shanghai, Shanghai 200065, China
  • Shanghai Tumor Hospital
    Shanghai, Shanghai 200065, China
  • Zhejiang Tumor Hospital
    Hangzhou, Zhejiang 310022, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Jan 2021, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2019
First posted
Jun 28, 2019
StartActual
Aug 6, 2019
Primary completionActual
Jan 21, 2021
CompletionActual
Jan 21, 2021
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04002622
Responsible party
Sponsor
First posted
Jun 28, 2019
Start date
Aug 6, 2019
Primary completion
Jan 21, 2021
Completion
Jan 21, 2021
Last update
Jan 25, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benmelstobart

Start the discussion